Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24 week, double-blind, randomized Phase 3 trial
- Author
- ROTH, Eli M1 ; TASKINEN, Marja-Riitta2 ; GINSBERG, Henry N3 ; KASTELEIN, John J. P4 ; COLHOUN, Helen M5 ; ROBINSON, Jennifer G6 ; MERLET, Laurence7 ; PORDY, Robert8 ; BACCARA-DINET, Marie T9
[1] The Sterling Research Group, Cincinnati, OH, United States
[2] Cardiovascular Research Unit, Diabetes and Obesity Research Program, University of Helsinki, Finland
[3] Columbia University, New York, NY, United States
[4] Department of Vascular Medicine, Academic Medical Center, Amsterdam, Netherlands
[5] Medical Research Institute, University of Dundee, Dundee, United Kingdom
[6] College of Public Health, University of Iowa, IA, United States
[7] Sanofi, Paris, France
[8] Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
[9] Sanofi, Montpellier, France - Source
International journal of cardiology. 2014, Vol 176, Num 1, pp 55-61, 7 p ; ref : 23 ref
- CODEN
- IJCDD5
- ISSN
- 0167-5273
- Scientific domain
- Cardiology, blood circulation, phlebology
- Publisher
- Elsevier, Shannon
- Publication country
- Ireland
- Document type
- Article
- Language
- English
- Author keyword
- Alirocumab Cholesterol-lowering drugs Hypercholesterolemia LDL-C Monoclonal antibodies PCSK9
- Keyword (fr)
- Anticorps monoclonal Cardiologie Cholestérol LDL Essai clinique phase III Etude comparative Etude double insu Ezétimibe Homme Hypercholestérolémie Hypolipémiant Immunomodulateur Immunothérapie Inhibiteur Lipide Lipoprotéine LDL Malade Pathologie de l'appareil circulatoire Randomisation Résultat Alirocumab Monothérapie Protéine PCSK9 Dyslipémie Hyperlipoprotéinémie Maladie métabolique Traitement
- Keyword (en)
- Monoclonal antibody Cardiology Cholesterol LDL Phase III trial Comparative study Double blind study Ezetimibe Human Hypercholesterolemia Antilipemic agent Immunomodulator Immunotherapy Inhibitor Lipids Lipoprotein LDL Patient Cardiovascular disease Randomization Result Alirocumab Dyslipemia Hyperlipoproteinemia Metabolic diseases Treatment
- Keyword (es)
- Anticuerpo monoclonal Cardiología Colesterol LDL Ensayo clínico fase III Estudio comparativo Estudio doble ciego Ezetimiba Hombre Hipercolesterolemia Hipolipemiante Inmunomodulador Inmunoterapia Inhibidor Lípido Lipoproteína LDL Enfermo Aparato circulatorio patología Aleatorización Resultado Alirocumab Dislipemia Hiperlipoproteinemia Metabolismo patología Tratamiento
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02Q Immunomodulators
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B12 Cardiology. Vascular system / 002B12A Heart
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B22 Metabolic diseases / 002B22A Disorders of blood lipids. Hyperlipoproteinemia
- Discipline
- Cardiology. Circulatory system Metabolic diseases Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 28711665
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1016/j.ijcard.2014.06.049 
https://dx.doi.org/10.1016/j.ijcard.2014.06.049
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:28:\"10.1016\/j.ijcard.2014.06.049\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:164:\"Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24 week, double-blind, randomized Phase 3 trial\";s:9:\"\u0000*\u0000jtitle\";s:35:\"International journal of cardiology\";s:9:\"\u0000*\u0000stitle\";s:15:\"Int. j. cardiol\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:3:\"176\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:2:\"55\";s:8:\"\u0000*\u0000epage\";s:2:\"61\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0167-5273\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"ROTH\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Eli M\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:22:\"TASKINEN, Marja-Riitta\";i:1;s:17:\"GINSBERG, Henry N\";i:2;s:20:\"KASTELEIN, John J. P\";i:3;s:16:\"COLHOUN, Helen M\";i:4;s:20:\"ROBINSON, Jennifer G\";i:5;s:16:\"MERLET, Laurence\";i:6;s:13:\"PORDY, Robert\";i:7;s:22:\"BACCARA-DINET, Marie T\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"IJCDD5\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:164:\"Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24 week, double-blind, randomized Phase 3 trial\";s:8:\"\u0000*\u0000place\";s:7:\"Shannon\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:28:\"10.1016\/j.ijcard.2014.06.049\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:164:\"Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24 week, double-blind, randomized Phase 3 trial\";s:9:\"\u0000*\u0000jtitle\";s:35:\"International journal of cardiology\";s:9:\"\u0000*\u0000stitle\";s:15:\"Int. j. cardiol\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:3:\"176\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:2:\"55\";s:8:\"\u0000*\u0000epage\";s:2:\"61\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0167-5273\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"ROTH\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Eli M\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:22:\"TASKINEN, Marja-Riitta\";i:1;s:17:\"GINSBERG, Henry N\";i:2;s:20:\"KASTELEIN, John J. P\";i:3;s:16:\"COLHOUN, Helen M\";i:4;s:20:\"ROBINSON, Jennifer G\";i:5;s:16:\"MERLET, Laurence\";i:6;s:13:\"PORDY, Robert\";i:7;s:22:\"BACCARA-DINET, Marie T\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"IJCDD5\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:164:\"Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24 week, double-blind, randomized Phase 3 trial\";s:8:\"\u0000*\u0000place\";s:7:\"Shannon\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:28:\"10.1016\/j.ijcard.2014.06.049\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:28:\"10.1016\/j.ijcard.2014.06.049\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:164:\"Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24 week, double-blind, randomized Phase 3 trial\";s:9:\"\u0000*\u0000jtitle\";s:35:\"International journal of cardiology\";s:9:\"\u0000*\u0000stitle\";s:15:\"Int. j. cardiol\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:3:\"176\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:2:\"55\";s:8:\"\u0000*\u0000epage\";s:2:\"61\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0167-5273\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"ROTH\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Eli M\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:22:\"TASKINEN, Marja-Riitta\";i:1;s:17:\"GINSBERG, Henry N\";i:2;s:20:\"KASTELEIN, John J. P\";i:3;s:16:\"COLHOUN, Helen M\";i:4;s:20:\"ROBINSON, Jennifer G\";i:5;s:16:\"MERLET, Laurence\";i:6;s:13:\"PORDY, Robert\";i:7;s:22:\"BACCARA-DINET, Marie T\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"IJCDD5\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:164:\"Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24 week, double-blind, randomized Phase 3 trial\";s:8:\"\u0000*\u0000place\";s:7:\"Shannon\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:28:\"10.1016\/j.ijcard.2014.06.049\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:164:\"Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24 week, double-blind, randomized Phase 3 trial\";s:9:\"\u0000*\u0000jtitle\";s:35:\"International journal of cardiology\";s:9:\"\u0000*\u0000stitle\";s:15:\"Int. j. cardiol\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:3:\"176\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:2:\"55\";s:8:\"\u0000*\u0000epage\";s:2:\"61\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0167-5273\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"ROTH\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Eli M\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:22:\"TASKINEN, Marja-Riitta\";i:1;s:17:\"GINSBERG, Henry N\";i:2;s:20:\"KASTELEIN, John J. P\";i:3;s:16:\"COLHOUN, Helen M\";i:4;s:20:\"ROBINSON, Jennifer G\";i:5;s:16:\"MERLET, Laurence\";i:6;s:13:\"PORDY, Robert\";i:7;s:22:\"BACCARA-DINET, Marie T\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"IJCDD5\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:164:\"Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24 week, double-blind, randomized Phase 3 trial\";s:8:\"\u0000*\u0000place\";s:7:\"Shannon\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
